Developer docs
API playgroundTry for free, no card

Search company profiles

Conatus Pharmaceuticals

Full company profile

uuid000jo3u

Namestring
Conatus Pharmaceuticals
Legal namestring
Conatus Pharmaceuticals
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Conatus Pharmaceuticals, listed on NASDAQ under ticker CNAT, is a clinical-stage biopharmaceutical company headquartered in San Diego that develops human therapeutics to treat liver failure and cancer. Its lead asset is emricasan, a first-in-class, orally active pan-caspase protease inhibitor designed to treat acute liver failure and liver fibrosis, supported by a patent portfolio of more than 130 issued patents covering composition of matter, validated drug targets, new chemical entities, drug-screening assays, diagnostics, antibodies, and broader programmed cell death (apoptosis) intellectual property. The company was founded in 2005, is led by co-founder Steven J. Mento, Ph.D. as President and CEO, and was built in part through the August 2010 acquisition of Idun Pharmaceuticals, with cumulative disclosed venture financing of roughly $62 million raised across rounds from 2006 through 2013 from investors including Aberdare Ventures, Advent Venture Partners, AgeChem, Bay City Capital, Gilde Healthcare, MPM Capital, and Roche Venture Fund.

Conatus also operates an online presence at conatuspharma.com that functions as a direct-to-consumer pharmacy selling generic medications (including generic Viagra/Sildenafil, Levitra/Vardenafil, Stendra/Avanafil, Vibramycin/Doxycycline, Tetracycline, and Aralen/Chloroquine) with flat-rate standard and express shipping and a 50-70% claimed price advantage over US pharmacy pricing, plus partnered programs with HealthPartners (Medication Adherence using smart pill bottles) and local nonprofits (Community Health Outreach mobile clinics). The Terms of Use are governed by California law and the website itself warns customers about fraudsters impersonating the Canadian pharmacy, indicating brand impersonation risk that complicates attribution of pharmacy-side activity to the listed biotech entity. Headcount is small (11-50 employees) and no commercial product revenue is disclosed, consistent with a clinical-stage therapeutics developer.

Short descriptiontext

Conatus Pharmaceuticals is a clinical-stage biopharmaceutical company (NASDAQ:CNAT) developing emricasan, a first-in-class caspase inhibitor for liver disease and cancer, backed by 130+ patents and venture funding from Aberdare, Advent, AgeChem, MPM, and Roche.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
online pharmacy, generic medications, prescription fulfillment, pharmaceutical retail, medication management
Industry2 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGACAK
Clinical Trial Pharmacy & IMP Management at Site
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Online Pharmacy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from selling generic and brand-name medications directly to consumers. Products include erectile dysfunction medications (Viagra generics, Levitra, Stendra), antibiotics (Vibramycin/Doxycycline, Tetracycline, Aralen/Chloroquine), and other pharmaceuticals. Pricing is volume-based with discounts for larger pack sizes.

conatuspharma.com
2Shipping Services
TypeTransaction Fee
Description

Revenue from shipping fees for medication delivery. Standard shipping at $10 flat rate, Express shipping at $30 flat rate. International shipping available to multiple countries.

conatuspharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Pricing details9 tiers
1Generic Sildenafil (Viagra) - Starting from $0.36 per pill
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Prices start from $0.36 per pill for generic Viagra. 30-pill pack costs $45.99 ($1.53/pill). Larger packs offer better per-unit pricing. 10% discount code available.

conatuspharma.com
2Vardenafil (Levitra Generic) - Starting from $0.88 per pill
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Prices start from $0.88 per pill for generic Levitra.

conatuspharma.com
3Avanafil (Stendra Generic) - Starting from $0.52 per pill
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Generic Stendra starts from $0.52 per pill.

conatuspharma.com
4Kamagra - Starting from $1.32 per pill
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Kamagra products available starting from $1.32 per pill.

conatuspharma.com
5Vibramycin (Doxycycline) Generic - $80-100 for 100 pills (100mg)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Generic Vibramycin priced at $80-100 for 100 pills (100mg dosage). Brand version runs $340-350 for 100 pills in Canada.

conatuspharma.com
6Tetracycline Generic - ~$45 for 100 pills (500mg) in Canada
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Generic Tetracycline costs approximately $45 for 100 pills (500mg) in Canada, compared to $130-400 in the US.

conatuspharma.com
7Aralen (Chloroquine) Generic - ~$60-65 for 30 tablets (250mg)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Generic Chloroquine priced at $60-65 for 30 tablets (250mg) in Canada, versus $160+ in the US.

conatuspharma.com
8Standard Shipping - $10 flat rate (7-21 business days)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standard shipping at $10 flat rate. Free shipping for orders over $200. Delivery within 7-21 business days.

conatuspharma.com
9Express Shipping - $30 flat rate (3-5 business days)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Express shipping at $30 flat rate. Delivery within 3-5 business days for urgent needs.

conatuspharma.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Conatus Pharmaceuticals operates a Canadian online pharmacy (conatuspharma.com) that dispenses generic and brand-name prescription and non-prescription medications directly to consumers. The platform offers an e-commerce catalog covering erectile dysfunction treatments, antibiotics, antimalarials and other therapeutics, with pharmacist support, prescription uploads, international shipping and volume-based discounts that price Canadian medications significantly below US benchmarks.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 30% reduction in emergency room visits
+2 more records
Product overview1 text field

Conatus Pharmaceuticals (Canadian Pharmacy) operates an online pharmacy platform offering a diverse portfolio of generic medications and healthcare services. The core product portfolio includes generic medications for erectile dysfunction (Generic Viagra/Sildenafil, Stendra/Avanafil, Levitra/Vardenafil), antibiotics (Vibramycin/Doxycycline, Tetracycline), and anti-malaria treatments (Aralen/Chloroquine). Supporting the medication catalog, the company offers patient care programs including Medication Management, Wellness and Prevention, and Specialty Pharmacy Services. Partnered programs with HealthPartners (Medication Adherence Program using smart pill bottles) and local nonprofits (Community Health Outreach with mobile clinics) extend the service ecosystem. Emricasan, a first-in-class caspase inhibitor for liver disease, represents the company's advanced pharmaceutical development pipeline.

Product and service9 records
1Generic Viagra (Sildenafil)
CategoryGeneric medication
Description

Sildenafil citrate tablets used to treat erectile dysfunction, offered in multiple dosage forms with volume discounts. Targeted at individual consumers seeking affordable ED medication.

2Vibramycin Generic (Doxycycline)
CategoryGeneric medication
Description

Wide-spectrum antibiotic for bacterial infections including respiratory tract infections, STDs and acne, supplied in 100mg and 200mg dosages. Targeted at individual consumers with valid prescriptions.

3Stendra Generic (Avanafil)
CategoryGeneric medication
Description

Generic version of Stendra (Avanafil) used to treat erectile dysfunction, intended for use under medical supervision. Targeted at adult male consumers.

4Levitra Generic (Vardenafil)
CategoryGeneric medication
Description

Vardenafil tablets for erectile dysfunction, typically recommended at 10mg with effects lasting 8-10 hours. Targeted at individual consumers seeking affordable ED treatment.

5Aralen Generic (Chloroquine)
CategoryGeneric medication
Description

Antiprotozoal and anti-inflammatory medication primarily used to treat and prevent malaria, also prescribed for rheumatoid arthritis, lupus and certain infectious liver and skin conditions. Targeted at consumers with valid prescriptions.

6Tetracycline Generic
CategoryGeneric medication
Description

Wide-spectrum antibiotic for bacterial infections including bronchitis, pneumonia, gonorrhea, chlamydia, Lyme disease and skin infections, available in 250mg and 500mg tablet forms. Targeted at individual consumers.

7Medication Management Program
CategoryService program
Description

Service providing personalized medication review and customized care plans to optimize medication therapy, assess drug interactions and ensure maximum benefit with least risk. Targeted at individual consumers on chronic or multi-drug regimens.

8Wellness and Prevention Program
CategoryService program
Description

Prevention-focused program offering health screenings (blood pressure, cholesterol, diabetes) and lifestyle coaching covering smoking cessation, weight management and stress management. Targeted at individual consumers.

9Specialty Pharmacy Services
CategoryService program
Description

Specialty services providing access to medications for rare or complex conditions, including insurance approvals and financial aid program support. Targeted at patients requiring specialty therapeutics.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partner supplier selected to ensure all products are top-notch. Provides wide selection of drugs and special promotions, ensuring security and easy shopping experience.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Flagship Medication Adherence Program using smart pill bottles and smartphone app notifications to monitor medication usage and send reminders. Over 75% of participants report improved adherence, with 30% reduction in ER visits.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Community Health Outreach initiative with mobile clinics visiting rural and urban underserved areas. Provides free health screenings, vaccinations, and educational workshops. Served over 10,000 individuals in the past year.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Novartis to ensure access to cutting-edge treatments and remain at the forefront of medical advancements.

5Abbott Laboratories
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration in cancer research and development as part of continued track record of collaborative drug discovery partnerships with large pharmaceutical companies.

conatuspharma.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

Clinical-stage and commercial biotech developing therapeutics for chronic liver diseases, notably obeticholic acid (OCA) for NASH/liver fibrosis — the most direct emricasan competitor in the same indications and prescriber audience.

TypeDirect peer
Description

Small-cap clinical-stage biotech advancing resmetirom for NASH and liver fibrosis. Highly comparable in size, stage, and mechanistic focus to Conatus' emricasan program.

TypeDirect peer
Description

Clinical-stage biotech developing elafibranor and other candidates for NASH and liver-related metabolic disorders; competes head-to-head with emricasan for the same hepatology opportunity.

TypeDirect peer
Description

Clinical-stage biotech with multiple liver/metabolic programs including NASH candidates, broadly comparable in therapeutic area and stage of development.

5Tobira Therapeutics
TypeDirect peer
Description

Pre-acquisition clinical-stage NASH peer developing cenicriviroc; pursued the same fibroinflammatory liver population targeted by emricasan before being acquired by Allergan. Closely comparable in scope and scale.

TypeDirect peer
Description

Small clinical-stage biotech developing GR-MD-02 for NASH and liver fibrosis — directly comparable in indication, modality of fibrosis treatment, and small-cap public profile.

TypeBroad incumbent
Description

Large-cap biopharma with a meaningful NASH and liver fibrosis pipeline (simtizumab, selonsertib) and eventual commercialization capacity across the same hepatology specialty audience.

TypeBroad incumbent
Description

Through its acquisition of Tobira and other deals, Allergan/AbbVie has assembled a NASH franchise directly competing with emricasan's target population and brings far broader development and commercial resources.

TypeEmerging player
Description

Small-cap clinical biotech with metabolic and liver-related programs; comparable in size and stage, with partially overlapping therapeutic focus rather than identical mechanism.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Conatus Pharmaceuticals

Online Pharmacyconatuspharma.com

Conatus Pharmaceuticals is a clinical-stage biopharmaceutical company (NASDAQ:CNAT) developing emricasan, a first-in-class caspase inhibitor for liver disease and cancer, backed by 130+ patents and venture funding from Aberdare, Advent, AgeChem, MPM, and Roche.

What Conatus Pharmaceuticals does

Conatus Pharmaceuticals, listed on NASDAQ under ticker CNAT, is a clinical-stage biopharmaceutical company headquartered in San Diego that develops human therapeutics to treat liver failure and cancer. Its lead asset is emricasan, a first-in-class, orally active pan-caspase protease inhibitor designed to treat acute liver failure and liver fibrosis, supported by a patent portfolio of more than 130 issued patents covering composition of matter, validated drug targets, new chemical entities, drug-screening assays, diagnostics, antibodies, and broader programmed cell death (apoptosis) intellectual property. The company was founded in 2005, is led by co-founder Steven J. Mento, Ph.D. as President and CEO, and was built in part through the August 2010 acquisition of Idun Pharmaceuticals, with cumulative disclosed venture financing of roughly $62 million raised across rounds from 2006 through 2013 from investors including Aberdare Ventures, Advent Venture Partners, AgeChem, Bay City Capital, Gilde Healthcare, MPM Capital, and Roche Venture Fund.

Conatus also operates an online presence at conatuspharma.com that functions as a direct-to-consumer pharmacy selling generic medications (including generic Viagra/Sildenafil, Levitra/Vardenafil, Stendra/Avanafil, Vibramycin/Doxycycline, Tetracycline, and Aralen/Chloroquine) with flat-rate standard and express shipping and a 50-70% claimed price advantage over US pharmacy pricing, plus partnered programs with HealthPartners (Medication Adherence using smart pill bottles) and local nonprofits (Community Health Outreach mobile clinics). The Terms of Use are governed by California law and the website itself warns customers about fraudsters impersonating the Canadian pharmacy, indicating brand impersonation risk that complicates attribution of pharmacy-side activity to the listed biotech entity. Headcount is small (11-50 employees) and no commercial product revenue is disclosed, consistent with a clinical-stage therapeutics developer.

Conatus Pharmaceuticals firmographics

Firmographics
Name
Conatus Pharmaceuticals
Legal name
Conatus Pharmaceuticals
Website
https://conatuspharma.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Conatus Pharmaceuticals is a clinical-stage biopharmaceutical company (NASDAQ:CNAT) developing emricasan, a first-in-class caspase inhibitor for liver disease and cancer, backed by 130+ patents and venture funding from Aberdare, Advent, AgeChem, MPM, and Roche.
Ownership category
akta.pro rank

Conatus Pharmaceuticals industry classification

Industry
Product category
Online Pharmacy
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGACAK
Clinical Trial Pharmacy & IMP Management at Site

Keywords

  • Online pharmacy
  • Generic medications
  • Prescription fulfillment
  • Pharmaceutical retail
  • Medication management

Where Conatus Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Conatus Pharmaceuticals business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from selling generic and brand-name medications directly to consumers. Products include erectile dysfunction medications (Viagra generics, Levitra, Stendra), antibiotics (Vibramycin/Doxycycline, Tetracycline, Aralen/Chloroquine), and other pharmaceuticals. Pricing is volume-based with discounts for larger pack sizes.
  2. Shipping Services: Revenue from shipping fees for medication delivery. Standard shipping at $10 flat rate, Express shipping at $30 flat rate. International shipping available to multiple countries.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goGeneric Sildenafil (Viagra) - Starting from $0.36 per pill
Unit PricingPay-as-you-goVardenafil (Levitra Generic) - Starting from $0.88 per pill
Unit PricingPay-as-you-goAvanafil (Stendra Generic) - Starting from $0.52 per pill
Unit PricingPay-as-you-goKamagra - Starting from $1.32 per pill
Unit PricingPay-as-you-goVibramycin (Doxycycline) Generic - $80-100 for 100 pills (100mg)
Unit PricingPay-as-you-goTetracycline Generic - ~$45 for 100 pills (500mg) in Canada
Unit PricingPay-as-you-goAralen (Chloroquine) Generic - ~$60-65 for 30 tablets (250mg)
Unit PricingPay-as-you-goStandard Shipping - $10 flat rate (7-21 business days)
Unit PricingPay-as-you-goExpress Shipping - $30 flat rate (3-5 business days)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Conatus Pharmaceuticals product offering

Product offering

Core offering

Conatus Pharmaceuticals operates a Canadian online pharmacy (conatuspharma.com) that dispenses generic and brand-name prescription and non-prescription medications directly to consumers. The platform offers an e-commerce catalog covering erectile dysfunction treatments, antibiotics, antimalarials and other therapeutics, with pharmacist support, prescription uploads, international shipping and volume-based discounts that price Canadian medications significantly below US benchmarks.

Product overview

Conatus Pharmaceuticals (Canadian Pharmacy) operates an online pharmacy platform offering a diverse portfolio of generic medications and healthcare services. The core product portfolio includes generic medications for erectile dysfunction (Generic Viagra/Sildenafil, Stendra/Avanafil, Levitra/Vardenafil), antibiotics (Vibramycin/Doxycycline, Tetracycline), and anti-malaria treatments (Aralen/Chloroquine). Supporting the medication catalog, the company offers patient care programs including Medication Management, Wellness and Prevention, and Specialty Pharmacy Services. Partnered programs with HealthPartners (Medication Adherence Program using smart pill bottles) and local nonprofits (Community Health Outreach with mobile clinics) extend the service ecosystem. Emricasan, a first-in-class caspase inhibitor for liver disease, represents the company's advanced pharmaceutical development pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Generic Viagra (Sildenafil) Sildenafil citrate tablets used to treat erectile dysfunction, offered in multiple dosage forms with volume discounts. Targeted at individual consumers seeking affordable ED medication.
  • Vibramycin Generic (Doxycycline) Wide-spectrum antibiotic for bacterial infections including respiratory tract infections, STDs and acne, supplied in 100mg and 200mg dosages. Targeted at individual consumers with valid prescriptions.
  • Stendra Generic (Avanafil) Generic version of Stendra (Avanafil) used to treat erectile dysfunction, intended for use under medical supervision. Targeted at adult male consumers.
  • Levitra Generic (Vardenafil) Vardenafil tablets for erectile dysfunction, typically recommended at 10mg with effects lasting 8-10 hours. Targeted at individual consumers seeking affordable ED treatment.
  • Aralen Generic (Chloroquine) Antiprotozoal and anti-inflammatory medication primarily used to treat and prevent malaria, also prescribed for rheumatoid arthritis, lupus and certain infectious liver and skin conditions. Targeted at consumers with valid prescriptions.
  • Tetracycline Generic Wide-spectrum antibiotic for bacterial infections including bronchitis, pneumonia, gonorrhea, chlamydia, Lyme disease and skin infections, available in 250mg and 500mg tablet forms. Targeted at individual consumers.
  • Medication Management Program Service providing personalized medication review and customized care plans to optimize medication therapy, assess drug interactions and ensure maximum benefit with least risk. Targeted at individual consumers on chronic or multi-drug regimens.
  • Wellness and Prevention Program Prevention-focused program offering health screenings (blood pressure, cholesterol, diabetes) and lifestyle coaching covering smoking cessation, weight management and stress management. Targeted at individual consumers.
  • Specialty Pharmacy Services Specialty services providing access to medications for rare or complex conditions, including insurance approvals and financial aid program support. Targeted at patients requiring specialty therapeutics.

Quantifiable outcome

  • 30% reduction in emergency room visits
  • +2 more outcomes

Companies that use Conatus Pharmaceuticals

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Conatus Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Conatus Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Global Canadian PharmacyminorChannel Partner/ Reseller/ DistributorPartner supplier selected to ensure all products are top-notch. Provides wide selection of drugs and special promotions, ensuring security and easy shopping experience.
  • HealthPartnerscoreStrategic or Co-development PartnerFlagship Medication Adherence Program using smart pill bottles and smartphone app notifications to monitor medication usage and send reminders. Over 75% of participants report improved adherence, with 30% reduction in ER visits.
  • Local Nonprofit OrganizationscoreStrategic or Co-development PartnerCommunity Health Outreach initiative with mobile clinics visiting rural and urban underserved areas. Provides free health screenings, vaccinations, and educational workshops. Served over 10,000 individuals in the past year.
  • NovartisminorStrategic or Co-development PartnerCollaboration with Novartis to ensure access to cutting-edge treatments and remain at the forefront of medical advancements.
  • Abbott LaboratoriesminorStrategic or Co-development PartnerCollaboration in cancer research and development as part of continued track record of collaborative drug discovery partnerships with large pharmaceutical companies.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Conatus Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Intercept Pharmaceuticals: Clinical-stage and commercial biotech developing therapeutics for chronic liver diseases, notably obeticholic acid (OCA) for NASH/liver fibrosis — the most direct emricasan competitor in the same indications and prescriber audience.
  • Madrigal Pharmaceuticals: Small-cap clinical-stage biotech advancing resmetirom for NASH and liver fibrosis. Highly comparable in size, stage, and mechanistic focus to Conatus' emricasan program.
  • Genfit: Clinical-stage biotech developing elafibranor and other candidates for NASH and liver-related metabolic disorders; competes head-to-head with emricasan for the same hepatology opportunity.
  • NGM Biopharmaceuticals: Clinical-stage biotech with multiple liver/metabolic programs including NASH candidates, broadly comparable in therapeutic area and stage of development.
  • Tobira Therapeutics: Pre-acquisition clinical-stage NASH peer developing cenicriviroc; pursued the same fibroinflammatory liver population targeted by emricasan before being acquired by Allergan. Closely comparable in scope and scale.
  • Galectin Therapeutics: Small clinical-stage biotech developing GR-MD-02 for NASH and liver fibrosis — directly comparable in indication, modality of fibrosis treatment, and small-cap public profile.

Broad incumbents

  • Gilead Sciences: Large-cap biopharma with a meaningful NASH and liver fibrosis pipeline (simtizumab, selonsertib) and eventual commercialization capacity across the same hepatology specialty audience.
  • Allergan / AbbVie: Through its acquisition of Tobira and other deals, Allergan/AbbVie has assembled a NASH franchise directly competing with emricasan's target population and brings far broader development and commercial resources.

Emerging players

  • Viking Therapeutics: Small-cap clinical biotech with metabolic and liver-related programs; comparable in size and stage, with partially overlapping therapeutic focus rather than identical mechanism.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Conatus Pharmaceuticals social profiles

Digital presence

Conatus Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Conatus Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Conatus Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Conatus Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Conatus Pharmaceuticals

What does Conatus Pharmaceuticals do?

Conatus Pharmaceuticals operates a Canadian online pharmacy (conatuspharma.com) that dispenses generic and brand-name prescription and non-prescription medications directly to consumers. The platform offers an e-commerce catalog covering erectile dysfunction treatments, antibiotics, antimalarials and other therapeutics, with pharmacist support, prescription uploads, international shipping and volume-based discounts that price Canadian medications significantly below US benchmarks.

Is Conatus Pharmaceuticals a public or private company?

Conatus Pharmaceuticals is a private company. It is currently operating.

When was Conatus Pharmaceuticals founded?

Conatus Pharmaceuticals was founded in 1997. It employs 11 to 50 people.

Where is Conatus Pharmaceuticals based?

Conatus Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

How does Conatus Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are shipping Services.

Who are Conatus Pharmaceuticals's main competitors?

Direct peers on record are Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Genfit, NGM Biopharmaceuticals, Tobira Therapeutics and Galectin Therapeutics. Broad incumbents are Gilead Sciences and Allergan / AbbVie. Viking Therapeutics is listed as an emerging player.

Does Conatus Pharmaceuticals have an API?

No public API is recorded for Conatus Pharmaceuticals.

What industry is Conatus Pharmaceuticals in?

Conatus Pharmaceuticals's product category is Online Pharmacy. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAGACAK, Clinical Trial Pharmacy & IMP Management at Site. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireHistogen Reports Second Quarter 2020 Earnings and Provides Business UpdateHistogen reported Q2 2020 financial results and provided a business update, including a reverse merger with Conatus and a NASDAQ listing. The company completed enrollment for its HST-001 Phase 1a/2b trial for androgenic alopecia, with topline data expected in Q4 2020, and filed an IDE for HST-002 as a dermal filler. Cash and cash equivalents as of June 30, 2020, were $10.4 million.GlobeNewswireLeading Independent Proxy Advisory Firms Recommend Conatus Pharmaceuticals Shareholders Vote in Favor of its Merger with Histogen and the Required Reverse Stock SplitISS and Glass Lewis recommended Conatus stockholders vote for its merger with Histogen and a reverse stock split, to be considered at a May 21, 2020 special meeting. The merger would give Histogen shareholders about 74% ownership, with closing expected by Q2 2020.GlobeNewswireHistogen Publishes Preclinical Data on its HST 004 Spinal Disc ProgramHistogen published preclinical data on its HST 004 spinal disc repair material, showing reduced inflammation and disc height increase in rabbit models. The company plans to file an investigational new drug application in 2021. It also announced a planned merger with Conatus Pharmaceuticals.GlobeNewswireThe Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020Conatus Pharmaceuticals adjourned its special meeting and reconvened it on May 21, 2020, to obtain quorum and stockholder approvals for its merger with Histogen. Over 95% of votes cast supported the merger, but the reverse stock split requires a majority of outstanding shares. The merger is expected to close by the end of Q2 2020.GlobeNewswireConatus Pharmaceuticals Reports First Quarter 2020 Financial Results and Strategic Process UpdateConatus Pharmaceuticals reported a Q1 2020 net loss of $3.5 million, down from $4.7 million in 2019, with no revenue. The company also announced a merger with Histogen, expected to close by Q2 2020, with Histogen shareholders owning about 74% of the combined company.GlobeNewswireHistogen Announces Investigational Device Exemption Application for HST 002Histogen submitted an Investigational Device Exemption application to the FDA for a Phase 1 trial of HST 002, a collagen-based dermal filler for facial folds and wrinkles. The trial will assess safety and tolerability versus placebo. The company also expects its merger with Conatus Pharmaceuticals to close in the second quarter of 2020.GlobeNewswireConatus Pharmaceuticals Reports 2019 Financial Results and Strategic Process UpdateConatus Pharmaceuticals reported Q4 2019 net loss of $2.7 million and full-year net loss of $11.4 million, with revenues of $0.5 million and $21.7 million respectively. The company also announced a merger with Histogen, expected to close by Q2 2020, with Histogen shareholders owning about 74% of the combined company.PR NewswireHistogen to Present at BIO CEO & Investor ConferenceHistogen Inc. announced a definitive merger agreement with Conatus Pharmaceuticals Inc. in an all-stock transaction valuing Histogen at $100 million and Conatus at $35.135 million, representing approximately a 155% premium to Conatus' recent share price. Under the terms, Histogen stockholders will own approximately 74% and Conatus stockholders approximately 26% of the combined company, which will operate under the Histogen name and trade on Nasdaq as "HSTO." The merger, expected to close by the end of Q2 2020 pending stockholder and regulatory approvals, will combine Histogen's regenerative medicine platform with Conatus' public company status.GlobeNewswireConatus Pharmaceuticals and Histogen Enter into Definitive Merger AgreementConatus Pharmaceuticals and Histogen entered a definitive all-stock merger agreement, with Histogen merging into a Conatus subsidiary. The deal values Histogen at $100 million, a 155% premium to Conatus' stock price, giving Histogen shareholders about 74% ownership. The combined company, named Histogen, is expected to close by Q2 2020.GlobeNewswireConatus Pharmaceuticals Appoints Kathy Scott as Independent Board MemberConatus Pharmaceuticals appointed Kathy Scott as an independent board member on Nov. 18, 2019. Scott, a managing director at Hale BioPharma Ventures, brings over 25 years of finance and M&A experience. The appointment aims to expand the board's perspective during its review of strategic alternatives with Oppenheimer & Co.